ANIX

Anixa Biosciences, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website anixa.com
Employees(FY) 4
ISIN US03528H1095

Performance

-6.31%

+1.16%

-4.55%

+6.84%

-21.52%

YTD

+2.87%

Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Advanced Technical Analysis

Technical Analysis of ANIX 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market appears to be un...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ANIX

Stock Rank

Recent News & Updates

2024-11-17 19:20
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial(Prnewswire)
2024-11-08 00:17
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting(Prnewswire)
2024-11-05 19:30
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting(Prnewswire)
2024-10-30 20:15
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024(Prnewswire)
2024-10-27 20:30
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting(Prnewswire)
2024-10-15 17:42
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial(Yahoo Finance)
2024-10-14 21:00
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial(Prnewswire)
2024-10-06 20:30
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development(Prnewswire)
2024-09-29 20:30
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial(Prnewswire)
2024-09-24 16:52
Anixa announces plans to launch Phase II breast cancer vaccine trial(Yahoo Finance)
2024-09-23 20:30
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine(Prnewswire)
2024-09-17 20:30
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference(Prnewswire)
2024-09-02 20:30
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium(Prnewswire)
2024-08-25 20:30
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-07-28 20:45
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting(Prnewswire)
2024-07-22 20:15
Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy(Prnewswire)
2024-07-22 19:45
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy(Yahoo Finance)
2024-07-16 20:00
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology(Prnewswire)
2024-07-14 20:30
Anixa Biosciences Announces $5 Million Share Repurchase Program(Prnewswire)
2024-07-14 20:00
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program(Yahoo Finance)
2024-06-23 20:45
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial(Prnewswire)
2024-06-04 09:52
ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024(Investorplace)
2024-05-27 18:10
7 Penny Biotech Stocks to Triple Your Investment(Investorplace)
2024-05-20 19:30
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial(Prnewswire)
2024-05-08 16:21
Anixa expands cancer vaccine collaboration with Cleveland Clinic(Yahoo Finance)
2024-05-07 20:25
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines(Prnewswire)
2024-05-06 21:15
Sidoti Events, LLC's Virtual May Micro-Cap Conference(Accesswire)
2024-05-05 20:05
Anixa Biosciences CEO Featured on 'Target: Cancer Podcast' by Oncologist Dr. Sanjay Juneja(Prnewswire)
2024-04-29 19:45
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024(Prnewswire)
2024-04-17 20:20
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.